- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05074836
Milk Supplementation and Bone Health in Children
Effects of Yili Child Formula Milk on Bone Health in 4-6 Year Children: a 12-month Randomized Controlled Trial
Objectives: to examine the effects of a Yili child formula milk and regular milk on bone health and growth in young children.
Study design: cluster randomized controlled trial.
Setting: kindergartens in Hui-ning County of Gansu Province, China (north west).
Participants: >=246 apparent healthy children aged 4-6 years old.
Interventions:
(I) Yili child formula milk (QQ star formula, SCI-PRO NUTR5+6TM), 195 ml *2 /day; (II) Yili regular milk (pure milk), 195ml*2 /day; (III) Controls: about 50g/d grain foods (containing 20-30 g carbohydrates), e.g. bread.
Interventional Duration: 12 months.
Outcome measures: determined at 0, 6 and 12 months post treatments. Primary outcomes: bone density and bone mineral contents at the forearm and heel, bone biomarkers.
Secondary outcomes: (1) anthropometric indices: weight, height, waist circumference, etc.; (2) immune status.
Other measures: dietary intakes, physical activities, general information, medical information, adverse of side effects.
Data Analyses: The one-year changes and percent changes in the primary and secondary outcomes will be compared among the 3 groups.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Gangshu
-
Lanzhou, Gangshu, China, 730000
- LanZhou University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged between 4-6 years;
- female and male
- Can be enrolled into kindergarten/school as a normal child.
- Be willing to drinking milk daily.
Exclusion Criteria:
- Milk allergy or intolerance, did not to be used to drinking milk;
- Had the following diseases/conditions confirmed by a hospital: serious diseases of heart, liver, kidney, brain, hematopoietic system, immunity, thyroid or cancer that need to be hospitalization for more than 1 week or take medication(s) for more than 1 month with the past two years.
- having infectious diseases, e.g., tuberculosis, hepatitis, etc.
- Taking vitamin D, calcium tables or nutrient package;
- Consumed more than 3 times (>600ml) milk each week in the previous month.
- Be not willing to provide informed consent, or have other conditions that were considered to be unsuitable for the study by the investigators.
- Increases of body health were out of the range between 5-8 cm in the last year.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Formula Milk
Formula milk designed for young children aged over 3 years; Dosage: 195 ml/time; Frequence: 2 times /day; Duration: 12 months |
Brand name: Yili (QQ star formula milk); Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years; Dosage: 195ml*2/d; Intervention duration: 12 months |
Aktiver Komparator: Regular milk
Regular milk (pure milk); Dosage: 195 ml/time; Frequence: 2 times /day; Duration: 12 months |
Brand name: Yili; Type: regular milk (pure milk); Dosage: 195ml*2/d; Intervention duration: 12 months |
Sonstiges: Control foods
Grain foods: e.g., bread; Dosage: 20-40 g/time; Frequence: 2 times /day; Duration: 12 months |
Brand: N/A; Food type: grain foods (e.g., bread); Dosage: 20-40g * 2/d grain foods Intervention duration: 12 months |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change from baseline bone mineral density (BMD) at 12 months
Zeitfenster: 0 and 12 months
|
BMD (g/cm2) determined by a dual energy x-ray absorptiometry (DXA) at the left forearm and heel
|
0 and 12 months
|
Change from baseline bone mineral density (BMD) at 6 months
Zeitfenster: 0 and 6 months
|
BMD (g/cm2) determined by DXA at the left forearm and heel
|
0 and 6 months
|
Change from baseline bone mineral contents (BMC) at 12 months
Zeitfenster: 0 and 12 months
|
BMC (g) determined by DXA at the left forearm and heel.
|
0 and 12 months
|
Change from baseline bone mineral contents (BMC) at 6 months
Zeitfenster: 0 and 6 months
|
BMC (g) determined by DXA at the left forearm and heel.
|
0 and 6 months
|
Change from baseline of bone-specific alkaline phosphatase at 12 months
Zeitfenster: 0 and 12 months
|
Bone turnover marker 1: Bone-specific alkaline phosphatase
|
0 and 12 months
|
Change from baseline of bone-specific alkaline phosphatase at 6 months
Zeitfenster: 0 and 6 months
|
Bone turnover marker 1: Bone-specific alkaline phosphatase
|
0 and 6 months
|
Change from baseline of osteocalcin at 12 months
Zeitfenster: 0 and 12 months
|
Bone turnover marker 2: osteocalcin
|
0 and 12 months
|
Change from baseline of osteocalcin at 6 months
Zeitfenster: 0 and 6 months
|
Bone turnover marker 2: osteocalcin
|
0 and 6 months
|
Change from baseline of C-terminal telopeptide of type I collagen at 12 months
Zeitfenster: 0 and 12 months
|
Bone turnover marker 3: C-terminal telopeptide of type I collagen
|
0 and 12 months
|
Change from baseline of C-terminal telopeptide of type I collagen at 6 months
Zeitfenster: 0 and 6 months
|
Bone turnover marker 3: C-terminal telopeptide of type I collagen
|
0 and 6 months
|
Change from baseline of tartrate resistant acid phosphatase at 12 months
Zeitfenster: 0 and 12 months
|
Bone turnover marker 4: tartrate resistant acid phosphatase
|
0 and 12 months
|
Change from baseline of tartrate resistant acid phosphatase at 6 months
Zeitfenster: 0 and 6 months
|
Bone turnover marker 4: tartrate resistant acid phosphatase
|
0 and 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change from baseline body weight at 12 months
Zeitfenster: 0 and 12 months
|
Anthropometric indices: body weight
|
0 and 12 months
|
Change from baseline body height at 12 months
Zeitfenster: 0 and 12 months
|
Anthropometric indices: body height
|
0 and 12 months
|
Change from baseline biomarker of body growth at 12 months
Zeitfenster: 0 and 12 months
|
Biomarker of body growth: insulin-like growth factor 1
|
0 and 12 months
|
Change from baseline immune globulin M (Ig M)at 12 months
Zeitfenster: 0 and 12 months
|
Immune status: Blood Ig M
|
0 and 12 months
|
Change from baseline immune globulin G (Ig G)at 12 months
Zeitfenster: 0 and 12 months
|
Immune status: Blood Ig G
|
0 and 12 months
|
Change from baseline immune globulin G (Ig A)at 12 months
Zeitfenster: 0 and 12 months
|
Immune status: Blood Ig A
|
0 and 12 months
|
Change from baseline whit blood cell at 12 months
Zeitfenster: 0 and 12 months
|
Immune status: whit blood cell
|
0 and 12 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Concentrations of blood total 25-hydroxide-vitamin D (25-OH-VD)
Zeitfenster: 0, 6 and 12 months
|
Serum 25-OH-VD
|
0, 6 and 12 months
|
Concentrations of blood parathyroid Hormone (PTH)
Zeitfenster: 0, 6 and 12 months
|
Serum PTH
|
0, 6 and 12 months
|
Nutritional status 1: Body weight
Zeitfenster: 0, 4, 8 and 12 months
|
Body weight (in kg)
|
0, 4, 8 and 12 months
|
Nutritional status 2: waist circumference
Zeitfenster: 0, 4, 8 and 12 months
|
Waist circumference (in cm)
|
0, 4, 8 and 12 months
|
Nutritional status 3: middle-arm circumference
Zeitfenster: 0, 4, 8 and 12 months
|
Middle-arm circumference (in cm)
|
0, 4, 8 and 12 months
|
Nutritional status 4: skinfold thickness
Zeitfenster: 0, 4, 8 and 12 months
|
Skinfold thickness (in mm)
|
0, 4, 8 and 12 months
|
Total consumption of milk and dairy food
Zeitfenster: 0, 4, 8 and 12 months
|
Total consumption of milk and dairy food (in ml/d)
|
0, 4, 8 and 12 months
|
Consumption of dietary energy
Zeitfenster: 0, 4, 8 and 12 months
|
Consumption of dietary energy (in kcal/d)
|
0, 4, 8 and 12 months
|
Consumption of dietary protein
Zeitfenster: 0, 4, 8 and 12 months
|
Consumption of dietary protein (in g/d)
|
0, 4, 8 and 12 months
|
Consumption of dietary calcium
Zeitfenster: 0, 4, 8 and 12 months
|
Consumption of dietary calcium (in mg/d)
|
0, 4, 8 and 12 months
|
Number of participants with treatment-related adverse events
Zeitfenster: 0, 4, 8 and 12 months
|
Adverse events : assessed by using questionnaires of medical conditions, medications related to milk intake
|
0, 4, 8 and 12 months
|
Child behaviors
Zeitfenster: 0 and 12 months
|
Child behaviours: assessed by using a Child behavior Questionnaire-- parent version.
The minimum and maximum values: 26-78; higher scores mean worse outcome.
|
0 and 12 months
|
Physical activity
Zeitfenster: 0, 4, 8 and 12 months
|
Physical activity (in MET, h/week): assessed by a Child Physical Activity Questionnaire
|
0, 4, 8 and 12 months
|
Concentrations of serum calcium
Zeitfenster: 0, 6 and 12 months
|
Serum calcium (mmol/L)
|
0, 6 and 12 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Yuming Chen, Ph.D., Sun Yat-sen University
- Studienstuhl: Zhifu Zhao, M. Phil, Inner Mongolia Dairy Technology Research Institute Co., Ltd.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SYSU-51000-20210723-0001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Knochendichte erhöht
-
InQpharm GroupAbgeschlossenBlutdruck | Low Density Lipoprotein-CholesterinspiegelDeutschland
-
Syneos HealthSynerK Pharmatech (Suzhou) LimitedRekrutierungErhöhtes Low-Density-Lipoprotein-CholesterinAustralien
-
Otsuka Pharmaceutical Co., Ltd.Aktiv, nicht rekrutierendHyper-Low-Density-Lipoprotein (LDL)-CholesterinämieJapan
-
Novartis PharmaceuticalsAbgeschlossenHoher Gehalt an Low-Density-Lipoprotein-CholesterinSchweiz
-
Otsuka Pharmaceutical Co., Ltd.AbgeschlossenHyper-Low-Density-Lipoprotein (LDL)-CholesterinämieJapan
-
Case Western Reserve UniversityAbgeschlossenRückenmarkstimulation | Hochfrequenz-Stimulation | High-Density-StimulationVereinigte Staaten
-
Universidade Norte do ParanáAbgeschlossenBone Mineral Density Quantitative Trait Locus 3Brasilien
-
Jordan Collaborating Cardiology GroupThe Cardiovascular Academy Group of the JCS; The Jordan Cardiac Society (JCS); Istishari Hospital Department of Clinical ResearchBeendetAtherosklerotisches kardiovaskuläres Risiko | Low-Density-Lipoprotein (LDL) CholesterinJordanien
-
Ain Shams UniversityAbgeschlossenBone Mineral Density Quantitative Trait Locus 3Ägypten
-
Guiyang Medical UniversityAbgeschlossenBone Mineral Density Quantitative Trait Locus 7
Klinische Studien zur Formula milk
-
Abbott NutritionAbgeschlossen
-
Heilongjiang Feihe Dairy Co. Ltd.Abgeschlossen
-
University of CologneAbgeschlossenChronisches NierenleidenDeutschland
-
University of ConnecticutDairy Management Inc.RekrutierungFettleibigkeit | DyslipidämienVereinigte Staaten
-
University of PittsburghNational Institute of Nursing Research (NINR)Abgeschlossen
-
Prolacta BioscienceAbgeschlossenSäugling, sehr niedriges GeburtsgewichtVereinigte Staaten
-
Fonterra Research CentreSprim Advanced Life SciencesAbgeschlossen
-
KK Women's and Children's HospitalNoch keine RekrutierungWachstumsfehler | Säugling mit sehr niedrigem Geburtsgewicht | Gespendete MuttermilchSingapur
-
Cook Group IncorporatedAbgeschlossen
-
Chinese University of Hong KongRekrutierung